The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis , Chapple et al. Eur Urol 2008;54:543
A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder, Novara et al. Eur Urol 2008; 54:740
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. Kaplan et al. BJU Int 2011; 107:1432
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Meek et al. Dig Dis Sci 2011; 56:7
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? Paquette et al. J Am Geriatr Soc 2011; 59:1332
Gray SL, Anderson ML, Dublin S et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015; 175: 401–7
Richardson K, Fox C, Maidment I et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 2018; 361: k1315
Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med. 2019; 179: 1084
Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Roehrborn et al. Urology 1999; 53:581
Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Porst et al. Urology 2013; 82:667
Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms sug- gestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. Giuliano et al. J Sex Med 2013; 10:857
Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?, Perachino et al. BJU Int 2010 ;105 :648
Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy Morote et al. J Urol 2007;178:1290
